Clinical

No prehydration prior to contrast-enhanced CT in patients with stage 3 CKD


 

Background: Postcontrast acute kidney injury (PC-AKI) is known to have a mild, often self-limiting, clinical course. Despite this, preventative measures are advised by international guidelines in high-risk patients.

Dr. Glenn Moulder, assistant professor, University of Virginia Health System, Charlottesville

Dr. Glenn Moulder


Study design: The Kompas trial was a multicenter, open-label, noninferiority randomized clinical trial in which 523 patients with stage 3 CKD were randomized to receive no hydration or prehydration with 250 mL of 1.4% sodium bicarbonate in a 1-hour infusion before undergoing elective contrast-enhanced CT. The primary endpoint was the mean relative increase in serum creatinine 2-5 days after contrast administration, compared with baseline.

Setting: Six hospitals in the Netherlands during April 2013–September 2016.

Synopsis: Of the 523 patients, (median age, 74 years), the mean relative increase in creatinine level 2-5 days after contrast administration compared with baseline was 3.0% in the no-prehydration group vs. 3.5% in the prehydration group. This demonstrates that withholding prehydration is noninferior to administrating prehydration. PC-AKI occurred in 7 of 262 patients in the no-prehydration group and 4 of 261 patients in the prehydration group and no patients required dialysis or developed heart failure. These results reassure us that prehydration with sodium bicarbonate can be safely omitted in patients with stage 3 CKD who undergo contrast-enhanced CT.

Bottom line: Prehydration with sodium bicarbonate is not needed to prevent additional renal injury in patients with CKD stage 3 undergoing contrast-enhanced CT imaging.

Citation: Timal RJ et al. Effect of no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention of postcontrast acute kidney injury in adults with chronic kidney disease: The Kompas Randomized Clinical Trial. JAMA Intern Med. 2020 Feb 17. doi: 10.1001/jamainternmed.2019.7428.

Dr. Moulder is assistant professor of medicine, section of hospital medicine, at the University of Virginia School of Medicine, Charlottesville.

Recommended Reading

New eGFR equation ‘less biased’ by age, kidney function; some disagree
The Hospitalist
DOACs show safety benefit in early stages of CKD
The Hospitalist
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
The Hospitalist
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
The Hospitalist
Thyroid hormone analogues can reverse NASH
The Hospitalist
Half of patients in hospital for COVID-19 get acute kidney injury
The Hospitalist
For patients with advanced CKD, low risk of nephrogenic systemic fibrosis with group II GBCAs
The Hospitalist
Fact or fiction? Intravascular contrast and acute kidney injury
The Hospitalist
Post–acute kidney injury proteinuria predicts subsequent kidney disease progression
The Hospitalist
Lack of fever in ESRD with S. aureus bacteremia is common
The Hospitalist
   Comments ()